key: cord-1014930-w9qanpa0
authors: Aziz, Muhammad; Fatima, Rawish; Haghbin, Hossein; Lee-Smith, Wade; Nawras, Ali
title: The Incidence and Outcomes of COVID-19 in IBD Patients: A Rapid Review and Meta-analysis
date: 2020-07-03
journal: Inflamm Bowel Dis
DOI: 10.1093/ibd/izaa170
sha: 5b74c85ca118e1fcdb86e254f8d7f72a23b92ffd
doc_id: 1014930
cord_uid: w9qanpa0

nan

We read with interest the article by Burgueño et al examining the pathophysiology behind lower prevalence of coronavirus disease 2019 in inflammatory bowel disease (IBD) patients. 1 To better understand the incidence and outcomes of COVID-19 in IBD, we queried the following databases through May 13, 2020: PubMed/ Medline, Embase, Cochrane, Web of Science, LitCOVID NIH, and WHO COVID-19 to identify studies reporting data pertaining to COVID-19 in IBD population.

Our search strategy yielded 8 studies for data extraction (Table 1) doi: 10.1093/ibd/izaa170 Published online 3 July 2020 I 2 = 76.4%), (4) mortality: 6.3% (95% CI, 2.5%-10.1%; I 2 = 0%).

The incidence of COVID-19 in IBD population was approximately 0.3% in our pooled cohort. This is somewhat encouraging, as the incidence is on the lower side compared with the general population (0.2%-4.0%). 2 The somewhat lower incidence is likely due to the lower expression of angiotensin converting enzyme 2 (ACE2) in gastrointestinal epithelial cells, which facilitates viral entry and subsequent infection of the host. Burgueño et al demonstrated that ACE2 is not increased in patients with IBD, and further therapy with immunosuppressants/ biologics may decrease the expression of these molecules, resulting in overall reassurance for IBD patients. 1 Bezzio et al argued continuation of therapy in IBD to avoid hospital/clinic visits and suppressing the "cytokine storm" associated with severe COVID-19. 3, 4 Thus, ongoing IBD therapy need not be discontinued in patients during the COVID-19 pandemic.

In conclusion, the current evidence (although weak) does suggest that the IBD population might be somewhat protected in developing COVID-19. The protection is further likely due to ongoing therapy of IBD and should not be discontinued. The incidence, severity, and outcomes related to COVID-19 needs to be compared in future studies for IBD and general population.

Expression of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD

Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts

Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study

Elevated interleukin-6 and severe COVID-19: a meta-analysis

Conflicts of Interest: The authors declare no conflicting or competing interest with respect to this manuscript.Supported by: No funding was received while preparing this manuscript. The manuscript is not under consideration for publication elsewhere. All authors have made substantive contributions to the study and have approved the submission of this article. MA is the article guarantor and is response for any correspondence.